Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling. You can also look for studies that offer remote participation from home!
This study seeks to understand the key differences and similarities in brain development between infants whose siblings do and do not have autism. Participants will be asked to make 3 visits to CHOP over time to complete cognitive and behavioral testing and a non-invasive MRI. Participants will be compensated for their time and receive a written feedback report.
This study is looking to recruit CHOP patients 5-30 years old with suspected/ confirmed bone sarcomas. The study is looking to evaluate a new MRI technique to evaluate bones and any mass in them. The study involved an additional imaging sequence performed at the same day as your clinically indicated MRI studies that allows researchers to better visualize the bones. This sequence takes about 30-60 minutes and may be done each time you have a clinically-indicated MRI (up to 3 times). If you're interested in learning more, please contact the study team.
The Craniofacial Pathologies biobank is a research study collecting and storing reamining surgical specimens from the cranium and face from diagnosed patients at CHOP with a congenital craniofacial anomaly. The main purpose of this longitudinal study is to help researchers discover the causes of craniofacial pathologies that may lead to new treatments.
The purpose of this study is to look at the safety and tolerability (how well you will react) of the study drug (HM15136) and to determine if it is effective for the treatment of Congenital Hyperinsulinism (HI). HM15136 is an experimental drug which is not approved by the FDA for the treatment of HI. HM15136 is stable and has a long effect in the body, only requiring it to be given (by injection) once a week. HM15136 is designed to act like glucagon, a hormone produced by the pancreas that helps the body maintain normal blood sugar levels by increasing the glucose produced in the liver and breaking down glycogen (a form of stored glucose) into the usable glucose form.
Participation lasts for up to 22 weeks and will involve up to 13 study visits. Study procedures include taking the study drug for 8 weeks, having electrocardiograms, wearing a continuous glucose monitor (CGM) and using a handheld glucose meter, having blood and urine tests, and completing an electronic diary.
The main risks of this study include: nausea, vomiting, diarrhea, abdominal pain, injection site reactions (swelling, itching, bleeding, or pain), loss of appetite, weight loss, high blood sugar. You may benefit if the study drug proves to be more effective than your current treatment plan in treating low blood sugar.
The goal of this study is to increase our understanding of how the brain is affected in infants with and without Down Syndrome. This may in turn provide clues that could eventually help identify therapeutic targets for intervention for individuals with Down Syndrome. We are enrolling infants with Down Syndrome between the ages of birth to 12 months old, and infants with typical development between the ages of birth to 6 months old. Expectant parents are encouraged to contact us.
Participants will be asked to make 3 visits to CHOP over time to complete cognitive and behavioral testing and a non-invasive MRI.
Participants will be compensated for their time and receive a written feedback report.
Although we know a lot about returning to sports, exercise, and school after concussion, we know very little about returning to drive after a concussion. Our Driving after Concussion study needs the help of both healthy and recently concussed teen partners in our research to understand how concussion affects driving behaviors in teens.
We are looking for healthy (have not had a concussion in the last year) and recently concussed teens who are 16.5-18 years old with a driver’s license and their own smartphone.
Our teen research partners may be asked to complete surveys about themselves and download smartphone applications that track symptoms associated with concussion and/or observe real-world driving behaviors. They may also be asked to come to CHOP's Driving Simulator Lab to complete a 3-hour session that includes surveys, clinical testing, and device testing along with a simulated driving assessment to observe driving behavior.
All teens who participate will be compensated for their time and effort.
The purpose of this study is to find out if alpelisib (BYL719;
the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease.
The purpose of this study is to find out how the brain learns to move in infants with and without brain injury. Some infants with brain injury later have cerebral palsy (CP), a condition that makes it hard for infants to learn how to move and control their balance, and others do not. Three groups of infants will participate- infants who had a brain injury and are at high risk for CP, infants who had a brain injury and are not at high risk for CP, and infants who are typically developing.
Are you interested learning about opportunities to participate in research? Sign up to receive information about new research studies at CHOP. It’s a great way to support the work of the Research Institute.